We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why You Should Add Huntsman (HUN) Stock to Your Portfolio
Read MoreHide Full Article
Huntsman Corporation’s (HUN - Free Report) stock looks promising at the moment. The chemical maker benefits from its investment in downstream businesses and differentiated product innovation as well as strategic acquisitions.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it is poised to carry the momentum ahead.
Let's see what makes this Zacks Rank #2 (Buy) stock an attractive investment option at the moment.
Price Performance
Shares of Huntsman have rallied 32.2% over the past three months against the 9.7% growth of its industry. It has also outperformed the S&P 500’s 8.9% rise over the same period.
Estimates Northbound
Earnings estimate revisions have the greatest impact on stock prices. Over the past month, the Zacks Consensus Estimate for Huntsman for the current year has increased around 45.2%. The consensus estimate for 2021 has also been revised 9.7% upward over the same time frame.
Positive Earnings Surprise History
Huntsman has outpaced the Zacks Consensus Estimate in three of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 21%, on average.
Growth Drivers in Place
Huntsman remains focused on growing its downstream specialty and formulation businesses and is shifting its MDI (methylene diphenyl diisocyanate) business from components to differentiated systems that typically have higher margins and lower volatility.
The company’s Polyurethanes segment, which accounted for more than half of its revenues last year, is well positioned for strong upside in the long term on the back of its focus on ramping up its high-value differentiated downstream portfolio. Substitution of MDI for less effective materials will remain a key driving factor for the MDI business.
Huntsman should also gain from synergies of strategic acquisitions. The buyout of Demilec, a leading manufacturer and distributor of spray polyurethane foam ("SPF") insulation systems in North America, is expected to offer significant synergies.
Moreover, the acquisition of Icynene-Lapolla, a leading North American manufacturer and distributor of SPF, is in line with Huntsman’s strategy of expanding its downstream polyurethanes business. The combination of Icynene-Lapolla with Demilec is expected to create the world's leading supplier of spray foam products.
The company, in May 2020, also completed the acquisition of CVC Thermoset Specialties, a North American specialty chemical producer that serves industrial composites, adhesives and coatings markets. The buyout is in sync with the company’s strategy of expanding its specialty Advanced Materials portfolio.
Per Huntsman, the integration of CVC Thermoset Specialties and Icynene-Lapolla buyouts is ahead of plans and the company expects to achieve total annualized targeted synergies of $35 million for these acquisitions by the end of 2021.
Moreover, the company last month announced updates on its third-quarter 2020 guidance. It expects adjusted EBITDA in the Polyurethanes segment to be at least 40% better compared with previous guidance provided during second-quarter earnings call.
Huntsman noted that the improved outlook reflects continued strength in construction related markets as well as better-than-expected improvement in automotive demand and higher overall margins.
Other top-ranked stocks worth considering in the basic materials space include Agnico Eagle Mines Limited (AEM - Free Report) , Yamana Gold Inc. and Eldorado Gold Corporation (EGO - Free Report) .
Agnico Eagle has a projected earnings growth rate of 91.8% for the current year. The company’s shares have rallied around 50% in a year. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Yamana Gold has an expected earnings growth rate of 84.6% for the current year. The company’s shares have surged around 75% in the past year. It currently carries a Zacks Rank #2.
Eldorado Gold has a projected earnings growth rate of 2,325% for the current year. The company’s shares have gained roughly 43% in a year. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Why You Should Add Huntsman (HUN) Stock to Your Portfolio
Huntsman Corporation’s (HUN - Free Report) stock looks promising at the moment. The chemical maker benefits from its investment in downstream businesses and differentiated product innovation as well as strategic acquisitions.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it is poised to carry the momentum ahead.
Let's see what makes this Zacks Rank #2 (Buy) stock an attractive investment option at the moment.
Price Performance
Shares of Huntsman have rallied 32.2% over the past three months against the 9.7% growth of its industry. It has also outperformed the S&P 500’s 8.9% rise over the same period.
Estimates Northbound
Earnings estimate revisions have the greatest impact on stock prices. Over the past month, the Zacks Consensus Estimate for Huntsman for the current year has increased around 45.2%. The consensus estimate for 2021 has also been revised 9.7% upward over the same time frame.
Positive Earnings Surprise History
Huntsman has outpaced the Zacks Consensus Estimate in three of the trailing four quarters. In this time frame, it has delivered an earnings surprise of 21%, on average.
Growth Drivers in Place
Huntsman remains focused on growing its downstream specialty and formulation businesses and is shifting its MDI (methylene diphenyl diisocyanate) business from components to differentiated systems that typically have higher margins and lower volatility.
The company’s Polyurethanes segment, which accounted for more than half of its revenues last year, is well positioned for strong upside in the long term on the back of its focus on ramping up its high-value differentiated downstream portfolio. Substitution of MDI for less effective materials will remain a key driving factor for the MDI business.
Huntsman should also gain from synergies of strategic acquisitions. The buyout of Demilec, a leading manufacturer and distributor of spray polyurethane foam ("SPF") insulation systems in North America, is expected to offer significant synergies.
Moreover, the acquisition of Icynene-Lapolla, a leading North American manufacturer and distributor of SPF, is in line with Huntsman’s strategy of expanding its downstream polyurethanes business. The combination of Icynene-Lapolla with Demilec is expected to create the world's leading supplier of spray foam products.
The company, in May 2020, also completed the acquisition of CVC Thermoset Specialties, a North American specialty chemical producer that serves industrial composites, adhesives and coatings markets. The buyout is in sync with the company’s strategy of expanding its specialty Advanced Materials portfolio.
Per Huntsman, the integration of CVC Thermoset Specialties and Icynene-Lapolla buyouts is ahead of plans and the company expects to achieve total annualized targeted synergies of $35 million for these acquisitions by the end of 2021.
Moreover, the company last month announced updates on its third-quarter 2020 guidance. It expects adjusted EBITDA in the Polyurethanes segment to be at least 40% better compared with previous guidance provided during second-quarter earnings call.
Huntsman noted that the improved outlook reflects continued strength in construction related markets as well as better-than-expected improvement in automotive demand and higher overall margins.
Huntsman Corporation Price and Consensus
Huntsman Corporation price-consensus-chart | Huntsman Corporation Quote
Stocks to Consider
Other top-ranked stocks worth considering in the basic materials space include Agnico Eagle Mines Limited (AEM - Free Report) , Yamana Gold Inc. and Eldorado Gold Corporation (EGO - Free Report) .
Agnico Eagle has a projected earnings growth rate of 91.8% for the current year. The company’s shares have rallied around 50% in a year. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Yamana Gold has an expected earnings growth rate of 84.6% for the current year. The company’s shares have surged around 75% in the past year. It currently carries a Zacks Rank #2.
Eldorado Gold has a projected earnings growth rate of 2,325% for the current year. The company’s shares have gained roughly 43% in a year. It currently carries a Zacks Rank #2.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>